Is Cannabis A Helpful Treatment For Sleep Apnea…?

Is Cannabis A Helpful Treatment For Sleep Apnea...?

The Scientific Evidence That Says Yes!

Recent scientific research conducted by the University of Illinois Department of Medicine discovered marijuana and it’s cannabinoids to be helpful in the management of sleep apnea. During an ordinary bout of sleep apnea and individuals respiration slows dramatically – occasionally ceasing entirely during certain sleep cycles.

In a summation of the study – the University of Illinois Department of medicine found that even trace amounts of (9)THC) tetrahydrocannabinol, one of the prime active cannabinoids in marijuana, monumentally improved the ability of individuals to overcome the adverse effects of sleep apnea, minus any unwanted medical side effects.

“Study Objective: Animal data suggest that (9)-TetraHydroCannabinol ((9)THC) stabilizes autonomic output during sleep, reduces spontaneous sleep-disordered breathing, and blocks serotonin-induced exacerbation of sleep apnea. On this basis, we examined the safety, tolerability, and efficacy of dronabinol ((9)THC), an exogenous Cannabinoid type 1 and type 2 (CB1 and CB2) receptor agonist in patients with Obstructive Sleep Apnea (OSA). Design and Setting: Proof of concept; single-center dose-escalation study of dronabinol. Participants: Seventeen adults with a baseline Apnea Hypopnea Index (AHI) ≥15/h. Baseline polysomnography (PSG) was performed after a 7-day washout of Continuous Positive Airway Pressure treatment. Intervention: Dronabinol was administered after baseline PSG, starting at 2.5 mg once daily. The dose was increased weekly, as tolerated, to 5 mg and finally to 10 mg once daily. Measurements and Results: Repeat PSG assessments were performed on nights 7, 14, and 21 of dronabinol treatment. Change in AHI (AHI, mean ± SD) was significant from baseline to night 21 (-14.1 ± 17.5; p = 0.007). No degradation of sleep architecture or serious adverse events was noted. Conclusion: Dronabinol treatment is safe and well-tolerated in OSA patients at doses of 2.5-10 mg daily and significantly reduces AHI in the short-term. These findings should be confirmed in a larger study in order to identify sub-populations with OSA that may benefit from cannabimimetic pharmacologic therapy.”